Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
ASP3550 is administered periodically to patients with prostate cancer. The primary efficacy variable is the effect of ASP3550 on the maintenance of serum testosterone suppression. In addition, the safety and pharmacokinetics of ASP3550 will be investigated.
Age
20–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven prostate cancer (adenocarcinoma) of all stages
A patient in whom endocrine treatment is indicated. Patients with rising serum PSA after having prostatectomy or radiotherapy performed with curative intention
Serum testosterone level above 2.2 ng/mL
An ECOG (Eastern Co-operative Oncology Group) P.S. (Performance Status) score of 0 to 2
Serum PSA level above 2 ng/mL
You may not be if
Previous or present endocrine treatment for prostate cancer.
However, patients who have undergone neoadjuvant/adjuvant endocrine therapy for a maximal duration of 6 months and in whom prostatectomy or radiotherapy was terminated at least 6 months
Treated with a 5α-reductase inhibitor
A candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within 12 months
Concurrent or a history of severe liver disease
Abnormal ECG such as long QTc
A patient receiving ASP3550 in past times
Administered drug in another clinical study or a post-market clinical study in the 28 days prior to the study
Clareo Health | Study to Find Maintenance Dose for Periodic Administration of ASP3550
